Clinical Trial Results:
A phase 3 open-label study to evaluate the immunogenicity and safety of a mixed (HEXA/PENTA/HEXA) primary series schedule that includes V419 (PR5I) at 2 and 6 months of age and Pediacel® at 4 months of age.
Summary
|
|
EudraCT number |
2012-004221-25 |
Trial protocol |
ES |
Global end of trial date |
27 Oct 2014
|
Results information
|
|
Results version number |
v1 |
This version publication date |
27 Apr 2016
|
First version publication date |
27 May 2015
|
Other versions |
v2 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
PRI02C
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01839188 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Sanofi Pasteur MSD S.N.C.
|
||
Sponsor organisation address |
162 avenue Jean Jaurès - CS 50712, Lyon Cedex 07, France, 69367
|
||
Public contact |
Clinical Trials Disclosure, Sanofi Pasteur MSD S.N.C., ClinicalTrialsDisclosure@spmsd.com
|
||
Scientific contact |
Clinical Trials Disclosure, Sanofi Pasteur MSD S.N.C., ClinicalTrialsDisclosure@spmsd.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
27 Oct 2014
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
27 Oct 2014
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
# To demonstrate that the mixed schedule induced acceptable responses for Hepatitis B (% of subjects with an anti-HBs titre ≥10 mIU/mL) 1 month after the third dose of the mixed schedule (i.e. at Month 7).
# To demonstrate that the mixed schedule induced acceptable responses for Haemophilus influenzae b (Hib) (% of subjects with an anti-polyribosylribitol phosphate [PRP] titre ≥0.15 µg/mL) 1 month after the third dose of the mixed schedule (i.e. at Month 7).
|
||
Protection of trial subjects |
Subjects in the study received the study vaccines (PR5I and Pediacel®) in line with the recommended infant immunisation schedule in Spain, and the immunisation schedule was consistent with other paediatric vaccines routinely given at the same age. NeisVac-C®, Prevenar 13®, and RotaTeq® were administered in accordance with their respective Summary of Product Characteristics.
Subjects with allergy to any of the vaccine components or history of a life-threatening reaction to a vaccine containing the same substances as the study vaccines (including concomitants) were not vaccinated.
Vaccines were administered by qualified study personnel.
After each vaccination, subjects were kept under observation for 30 minutes to ensure their safety.
Adequate treatment provisions, including epinephrine, were available for immediate use, should an anaphylactic or anaphylactoid reaction occurred.
|
||
Background therapy |
Infants were previously vaccinated with only 1 dose of monovalent Hepatitis B vaccine, within the 3 days after birth, outside of the study context. | ||
Evidence for comparator |
Not applicable. | ||
Actual start date of recruitment |
01 May 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Spain: 385
|
||
Worldwide total number of subjects |
385
|
||
EEA total number of subjects |
385
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
385
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||
Recruitment
|
|||||||||||
Recruitment details |
Study subjects were enrolled in 12 active sites in Spain. Enrolment started on 01 May 2013. | ||||||||||
Pre-assignment
|
|||||||||||
Screening details |
Overall, 16 investigational sites were evaluated and considered eligible to screen subjects for study participation. Of these 16 sites, 12 screened 385 subjects in total. Of the 385 screened subjects, 100% were enrolled and vaccinated. | ||||||||||
Period 1
|
|||||||||||
Period 1 title |
Overall trial (overall period)
|
||||||||||
Is this the baseline period? |
Yes | ||||||||||
Allocation method |
Not applicable
|
||||||||||
Blinding used |
Not blinded | ||||||||||
Arms
|
|||||||||||
Arm title
|
All subjects | ||||||||||
Arm description |
Subjects received: # At 2 months of age, 1 dose of PR5I (DTaP-HB-IPV-Hib = Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine (adsorbed)) + 1 dose of NeisVac-C (MCC = Meningococcal group C polysaccharide Conjugate vaccine adsorbed) + 1 dose of Prevenar 13 (PCV-13 = Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)) by intramuscular route (IM) + 1 dose of RotaTeq (pentavalent combination live vaccine of 5 human-bovine reassortant rotavirus strains) by oral route. # At 4 months of age, 1 dose of Pediacel (DTaP-IPV-Hib) + 1 dose of NeisVac-C (MCC) + 1 dose of Prevenar 13 (PCV-13) by IM route + 1 dose of RotaTeq by oral route. # At 6 months of age, 1 dose of PR5I (DTaP-HB-IPV-Hib) by IM route + 1 dose of RotaTeq by oral route. | ||||||||||
Arm type |
Experimental | ||||||||||
Investigational medicinal product name |
PR5I vaccine
|
||||||||||
Investigational medicinal product code |
DTaP-HB-IPV-Hib
|
||||||||||
Other name |
V419
|
||||||||||
Pharmaceutical forms |
Suspension for injection
|
||||||||||
Routes of administration |
Intramuscular use
|
||||||||||
Dosage and administration details |
0.5 mL, intramuscular route (left upper thigh), one dose at 2 and 6 months of age.
|
||||||||||
Investigational medicinal product name |
Pediacel®
|
||||||||||
Investigational medicinal product code |
DTaP-IPV-Hib
|
||||||||||
Other name |
|||||||||||
Pharmaceutical forms |
Suspension for injection in pre-filled syringe
|
||||||||||
Routes of administration |
Intramuscular use
|
||||||||||
Dosage and administration details |
0.5 mL, intramuscular route (left upper thigh), one dose at 4 months of age.
|
||||||||||
Investigational medicinal product name |
NeisVac-C®
|
||||||||||
Investigational medicinal product code |
MCC
|
||||||||||
Other name |
|||||||||||
Pharmaceutical forms |
Suspension for injection in pre-filled syringe
|
||||||||||
Routes of administration |
Intramuscular use
|
||||||||||
Dosage and administration details |
0.5 mL, intramuscular route (right upper thigh), one dose at 2 and 4 months of age.
NeisVac-C and Prevenar 13 were both administered in the right upper thigh, provided that the injections were separated by at least 5 cm.
|
||||||||||
Investigational medicinal product name |
Prevenar 13®
|
||||||||||
Investigational medicinal product code |
PCV-13
|
||||||||||
Other name |
|||||||||||
Pharmaceutical forms |
Suspension for injection in pre-filled syringe
|
||||||||||
Routes of administration |
Intramuscular use
|
||||||||||
Dosage and administration details |
0.5 mL, intramuscular route (right upper thigh), one dose at 4 months of age.
NeisVac-C and Prevenar 13 were both administered in the right upper thigh, provided that the injections were separated by at least 5 cm.
|
||||||||||
Investigational medicinal product name |
RotaTeq®
|
||||||||||
Investigational medicinal product code |
RotaTeq
|
||||||||||
Other name |
|||||||||||
Pharmaceutical forms |
Oral solution in single-dose container
|
||||||||||
Routes of administration |
Oral use
|
||||||||||
Dosage and administration details |
2 mL, oral route, one dose at 2 and 6 months of age.
RotaTeq was administered orally, prior to any other vaccine administration to avoid the subject to spit up RotaTeq when crying.
|
||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall trial (overall period)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received: # At 2 months of age, 1 dose of PR5I (DTaP-HB-IPV-Hib = Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine (adsorbed)) + 1 dose of NeisVac-C (MCC = Meningococcal group C polysaccharide Conjugate vaccine adsorbed) + 1 dose of Prevenar 13 (PCV-13 = Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)) by intramuscular route (IM) + 1 dose of RotaTeq (pentavalent combination live vaccine of 5 human-bovine reassortant rotavirus strains) by oral route. # At 4 months of age, 1 dose of Pediacel (DTaP-IPV-Hib) + 1 dose of NeisVac-C (MCC) + 1 dose of Prevenar 13 (PCV-13) by IM route + 1 dose of RotaTeq by oral route. # At 6 months of age, 1 dose of PR5I (DTaP-HB-IPV-Hib) by IM route + 1 dose of RotaTeq by oral route. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
All subjects
|
||
Reporting group description |
Subjects received: # At 2 months of age, 1 dose of PR5I (DTaP-HB-IPV-Hib = Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine (adsorbed)) + 1 dose of NeisVac-C (MCC = Meningococcal group C polysaccharide Conjugate vaccine adsorbed) + 1 dose of Prevenar 13 (PCV-13 = Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)) by intramuscular route (IM) + 1 dose of RotaTeq (pentavalent combination live vaccine of 5 human-bovine reassortant rotavirus strains) by oral route. # At 4 months of age, 1 dose of Pediacel (DTaP-IPV-Hib) + 1 dose of NeisVac-C (MCC) + 1 dose of Prevenar 13 (PCV-13) by IM route + 1 dose of RotaTeq by oral route. # At 6 months of age, 1 dose of PR5I (DTaP-HB-IPV-Hib) by IM route + 1 dose of RotaTeq by oral route. |
|
|||||||||||
End point title |
Proportion of subjects with anti-HBs titre ≥10 mIU/mL one month after the third dose of the mixed schedule (i.e. at Month 7) [1] | ||||||||||
End point description |
Percentage of subjects with an anti-Hepatitis B (HBs) titre ≥10 mIU/mL (measured by Hepatitis B enhanced chemiluminescence assay), one month after the third dose of the mixed schedule.
Analysis was done on the PR5I-Per Protocol set (PR5I-PPS).
The immune response to PR5I vaccine was considered as acceptable if the lower bound of the two-sided 95% CI of the percentage of subjects with anti-HBs titre ≥10 mIU/mL one month after the third dose of the mixed schedule was greater than 90%.
The success of the study required that the primary objective was achieved for both Hepatitis B and PRP.
Note: (N= ***) represents the number of assessed subjects.
|
||||||||||
End point type |
Primary
|
||||||||||
End point timeframe |
One month after the third dose of the mixed schedule (i.e. at Month 7).
|
||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a single arm study, subjects were all enrolled in the same treatment group. The success of the study required that the primary objective was achieved for both Hepatitis B and PRP. For Hepatitis B, the immune response to PR5I vaccine was considered as acceptable if the lower bound of the 2-sided 95% CI of the % of subjects with anti-HBs titre ≥10 mIU/mL one month after the third dose of the mixed schedule was greater than 90%. The lower bound was 97.2%. |
|||||||||||
|
|||||||||||
Notes [2] - PR5I-PPS |
|||||||||||
No statistical analyses for this end point |
|
|||||||||||
End point title |
Proportion of subjects with anti-Hib titre ≥0.15 µg/mL one month after the third dose of the mixed schedule (i.e. at Month 7) [3] | ||||||||||
End point description |
Percentage of subjects with an anti-polyribosylribitol phosphate (PRP) titre ≥0.15 μg/mL for Haemophilus influenzae type b (Hib), one month after the third dose of the mixed schedule. Anti-PRP titres were measured by radioimmunoassay (RIA).
Analysis was done on the PR5I-Per Protocol set (PR5I-PPS).
The immune response to PR5I vaccine was considered as acceptable if the lower bound of the two-sided 95% CI of the percentage of subjects with anti-PRP titre ≥0.15 μg/mL one month after the third dose of the mixed schedule was greater than 80%.
The success of the study required that the primary objective was achieved for both Hepatitis B and PRP.
Note: (N= ***) represents the number of assessed subjects.
|
||||||||||
End point type |
Primary
|
||||||||||
End point timeframe |
One month after the third dose of the mixed schedule (i.e. at Month 7).
|
||||||||||
Notes [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a single arm study, subjects were all enrolled in the same treatment group. The success of the study required that the primary objective was achieved for both Hepatitis B and PRP. For Hib (PRP), the immune response to PR5I vaccine was considered as acceptable if the lower bound of the 2-sided 95% CI of the % of subjects with anti-PRP titre ≥0.15 µg/mL one month after the third dose of the mixed schedule was greater than 80%. The lower bound was 99%. |
|||||||||||
|
|||||||||||
Notes [4] - PR5I-PPS |
|||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||
End point title |
Geometric Mean Titres or Concentrations of all PR5I vaccine antigens one month after the third dose of the mixed schedule (i.e. at Month 7) | ||||||||||||||||||||||||||||||
End point description |
Antibody titres or concentrations were measured for Hepatitis B (HBs) by enhanced chemiluminescence assay (mIU/mL), for Haemophilus influenzae type b (Hib, anti-PRP antibodies) by radioimmunoassay (RIA) (µg/mL), for diphtheria (D) by Metabolic Inhibition Test (MIT) (IU/mL), for tetanus (T) by Enzyme-Linked Immunosorbent Assay (ELISA) (IU/mL), for inactivated poliovirus types 1, 2 & 3 (IPV1, IPV2 & IPV3) by MIT (1/dil), and for pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN) and fimbriae types (FIM) 2&3 by ELISA (EU/mL).
Analysis was done on the PR5I-Per Protocol set (PR5I-PPS).
Note: (N=***) represents the number of assessed subjects.
|
||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||
End point timeframe |
One month after the third dose of the mixed schedule (i.e. at Month 7): one dose of PR5I at Month 2, one dose of Pediacel at Month 4, and one dose of PR5I at Month 6.
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Response rates for Haemophilus influenzae type b, diphtheria, tetanus, pertussis, and inactivated poliovirus types 1, 2 & 3 one month after the third dose of the mixed schedule (i.e. at Month 7) | ||||||||||||||||||||||||
End point description |
Percentages of subjects with anti-PRP titre ≥1 µg/mL (measured by radioimmunoassay (RIA)) for Hib, anti-D concentration ≥0.01 IU/mL and anti-D concentration ≥0.10 IU/mL (measured by Metabolic Inhibition Test (MIT)) for diphtheria, anti-T concentration ≥0.01 IU/mL and anti-T concentration ≥0.10 IU/mL (measured by Enzyme-Linked Immunosorbent Assay (ELISA)) for tetanus, anti-IPV titre ≥8 (1/dil) (measured by MIT) for inactivated poliovirus types 1, 2 & 3 (IPV1, IPV2 & IPV3), one month after the third dose of the mixed schedule.
Analysis was done on the PR5I-Per Protocol set (PR5I-PPS).
Note: (N=***) represents the number of assessed subjects.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
One month after the third dose of the mixed schedule (i.e. at Month 7): one dose of PR5I at Month 2, one dose of Pediacel at Month 4, and one dose of PR5I at Month 6.
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||
End point title |
Response rate for Meningococcal group C polysaccharide Conjugate (MCC) one month after the second dose of MCC vaccine (i.e. at Month 5) | ||||||||||
End point description |
Percentages of subjects with anti-MCC titre ≥8 (1/dil) measured by Serum Bactericidal Antibody with rabbit complement Assay (rBSA) for Meningococcal serogroup C Conjugate (MCC), one month after the second dose of MCC vaccine (i.e. at Month 5), when used concomitantly with the mixed schedule.
Analysis was done on the MCC-Per Protocol set (MCC-PPS).
Note: (N=***) represents the number of assessed subjects.
|
||||||||||
End point type |
Secondary
|
||||||||||
End point timeframe |
One month after the second dose of MCC vaccine (i.e. at Month 5) when used concomitantly with the mixed schedule: one dose of MCC at Month 2 and one dose of MCC at Month 4.
|
||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||||
End point title |
Geometric Mean Titre of MCC one month after the second dose of MCC vaccine (i.e. at Month 5) | ||||||||||
End point description |
Antibody titres were measured for Meningococcal group C polysaccharide Conjugate (MCC) by Serum Bactericidal Antibody with rabbit complement Assay (rBSA) (1/dil).
Analysis was done on the MCC-Per Protocol set (MCC-PPS).
Note: (N=***) represents the number of assessed subjects.
|
||||||||||
End point type |
Secondary
|
||||||||||
End point timeframe |
One month after the second dose of MCC vaccine (i.e. at Month 5) when used concomitantly with the mixed schedule: one dose of MCC at Month 2 and one dose of MCC at Month 4.
|
||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Proportion of subjects with at least one body temperature ≥38.0°C from Day 1 to Day 5 after each vaccination | ||||||||||||||
End point description |
The subject’s parent(s)/legal representative recorded all adverse events (AEs). As per protocol instructions, axillary route was used for daily temperature measurement, in the evening, in most of the subjects (rectal route was used in 3 subjects, and oral route in 1 subject).
Temperatures were based on actual temperatures recorded with no adjustements to the route of assessment. The % of subjects with at least one body temperature ≥38.0°C from Day 1 to Day 5 after each vaccination was calculated.
Four Safety sets (SS) were defined in this study: SS1 after vaccination 1 (Month 2), SS2 after vaccination 2 (Month 4), SS3 after vaccination 3 (Month 6) and overall (all subjects who received at least 1 dose of 1 study vaccine, with any safety follow-up).
% are based on the number of subjects with available temperature data within the 5 days following each vaccination.
Note: (N=***) represents the number of subjects with available temperature.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Day 1 to Day 5 after each vaccination (V): V1 (PR5I + MCC + Prevenar 13 + RotaTeq), V2 (Pediacel + MCC + Prevenar 13 + RotaTeq) & V3 (PR5I + RotaTeq), respectively administered at 2, 4 and 6 months of age, and after any vaccination.
|
||||||||||||||
|
|||||||||||||||
Notes [5] - Subjects with at least 1 dose of 1 study vaccine |
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||
End point title |
Incidence of solicited Injection-Site Reactions related to PR5I or Pediacel from Day 1 to Day 5 after any vaccination and after each vaccination | ||||||||||||||||||||||||||||||||||||||||
End point description |
The subject’s parent(s)/legal representative recorded all adverse events (AEs) on the vaccine report card (VRC).
AEs at injection sites were always considered as related to vaccine (Injection-Site Reactions (ISRs)).
Solicited ISRs (erythema, pain and swelling that occurred from Day 1 to Day 5 following PRI5 or Pediacel vaccination) were presented after each vaccination and after any vaccination.
Four Safety sets (SS) were defined in this study: SS1 after vaccination 1 (at Month 2), SS2 after vaccination 2 (at Month 4), SS3 after vaccination 3 (at Month 6) and Global SS (all subjects who received at least 1 dose of 1 study vaccine, with any safety data).
Analysis was done on the Safety sets.
|
||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 1 to Day 5 after each vaccination (V): V1 (PR5I + MCC + Prevenar 13 + RotaTeq), V2 (Pediacel + MCC + Prevenar 13 + RotaTeq) & V3 (PR5I + RotaTeq), respectively administered at 2, 4 and 6 months of age, and after any vaccination.
|
||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||
Notes [6] - All subjects who received at least 1 dose of 1 study vaccine |
|||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||
End point title |
Incidence of solicited Injection-Site Reactions related to MCC from Day 1 to Day 5 after any vaccination and after each vaccination | ||||||||||||||||||||||||||||||||
End point description |
The subject’s parent(s)/legal representative recorded all adverse events (AEs) on the vaccine report card (VRC).
Adverse events at injection sites were always considered as related to vaccine (Injection-Site Reactions (ISRs)).
Solicited Injection-Site Reactions (ISRs) (erythema, pain and swelling that were collected from Day 1 to Day 5 following each vaccination with MCC) are presented after each vaccination and following any vaccination.
Four Safety sets (SS) were defined in this study: SS1 after vaccination 1 (at Month 2), SS2 after vaccination 2 (at Month 4), SS3 after vaccination 3 (at Month 6) and Global SS (all subjects who received at least 1 dose of 1 study vaccine, with any safety follow-up).
Analysis was done on the Safety sets.
|
||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||
End point timeframe |
Day 1 to Day 5 after vaccination 1 (PR5I +, MCC + Prevenar 13 + RotaTeq) & vaccination 2 (Pediacel+ MCC + Prevenar 13 + RotaTeq), respectively administered at 2 and 4 months of age, and after any vaccination.
|
||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Notes [7] - All subjects who received at least 1 dose of 1 study vaccine |
|||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Incidence of solicited systemic AEs (crying, decreased appetite, irritability, somnolence and vomiting) from Day 1 to Day 5 after each vaccination and after any vaccination | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
The subject’s parent(s)/legal representative recorded all adverse events (AEs) on the vaccine report card (VRC).
Solicited systemic AEs (crying, decreased appetite, irritability, somnolence, pyrexia, and vomiting that occurred from Day 1 to Day 5) were collected daily. The investigator had to assess whether these systemic AEs were related or not to the vaccine. All (related and unrelated) are displayed here.
Temperature ≥38°C (fever or pyrexia) are presented in a specific endpoint.
Four Safety sets (SS) were defined in this study: SS1 after vaccination 1 (at Month 2), SS2 after vaccination 2 (at Month 4), SS3 after vaccination 3 (at Month 6) and Global SS (all subjects who received at least 1 dose of 1 study vaccine, with any safety follow-up).
Analysis was done on the Safety sets.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 1 to Day 5 after each vaccination (V): V1 (PR5I + MCC + Prevenar 13 + RotaTeq), V2 (Pediacel + MCC + Prevenar 13 + RotaTeq) & V3 (PR5I + RotaTeq), respectively administered at 2, 4 and 6 months of age, and after any vaccination.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [8] - All subjects who received at least 1 dose of 1 study vaccine |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Unsolicited adverse events (AEs) were recorded daily from Day 1 to Day 15 following each vaccination.
Unsolicited serious AEs (SAEs) were collected from the first vaccination to the last visit.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Every subject was counted a single time for each applicable specific adverse event (AE).
A subject with multiple AEs within a system organ class (SOC) was counted a single time for that SOC.
For each AE, the number of occurrences from Day 1 to Day 15 was by convention equal to the number of subjects reporting the AE.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
17.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
All subjects
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received # At 2 months of age, 1 dose of PR5I + 1 dose of MCC + 1 dose of PCV-13 by IM route + 1 dose of RotaTeq by oral route; # at 4 months of age, 1 dose of Pediacel + 1 dose of MCC + 1 dose of PCV-13 by IM route + 1 dose of RotaTeq by oral route; # at 6 months of age, 1 dose of PR5I by IM route + 1 dose of RotaTeq by oral route. Numbers and % of subjects reporting at least 1 SAE and at least 1 unsolicited non-serious ISR or AE with incidence ≥2% are presented below. 12 subjects reported at least 1 SAE. If each unsolicited ISR or AE with incidence ≥2% was reported by a different subject, 128 subjects would have reported at least 1 unsolicited ISR or AE with incidence ≥2%. Overall, 21 (5.5%) subjects reported at least 1 unsolicited ISR at PR5I or Pediacel site, and 7 (1.8%) at MCC site; 163 (42.3%) subjects reported at least 1 unsolicited non-serious systemic AE, and 15 (3.9%) at least 1 vaccine-related unsolicited non-serious systemic AE. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 2% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |